Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive Non-Small Cell Lung Cancer

The primary objective of the study is to compare the **event-free survival (EFS)** of participants with Stage II-IIIA **RET fusion-positive non-small cell lung cancer (NSCLC)** treated with **selpercatinib** versus placebo. This comparison is clinically relevant as it aims to determine the efficacy of selpercatinib as an adjuvant therapy following definitive locoregional treatment, potentially improving outcomes for patients with this specific genetic mutation in NSCLC.

The clinical trial involves a total of **152 participants** diagnosed with **RET fusion-positive non-small cell lung cancer (NSCLC)**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults. Participants were selected based on their diagnosis of early-stage NSCLC and must have already undergone and recovered from surgery or radiation. They are required to be in fair to good health and must agree to use highly effective birth control during the study. The trial includes a vulnerable population, indicating that special considerations are in place to protect these participants. Lifestyle factors such as diet and physical activity are not specified in the available data.

The clinical trial is designed as a **randomized**, **double-blind**, **placebo-controlled** Phase 3 study to evaluate the efficacy of **selpercatinib** as an adjuvant treatment in participants with Stage IB-IIIA **RET fusion-positive non-small cell lung cancer (NSCLC)**. The primary objective is to compare event-free survival (EFS) between participants treated with selpercatinib and those receiving a placebo. The trial is expected to run from July 31, 2021, to August 14, 2032, with participant involvement lasting up to one year, depending on individual treatment response and adherence to protocol.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as having early-stage NSCLC, recovery from surgery or radiation, and being in fair to good health. Following randomization, participants will receive either selpercatinib or a placebo, administered orally. Regular follow-up visits will be scheduled to monitor safety, adherence, and efficacy, with assessments conducted by investigators. The end-of-study visit will conclude the participant's involvement, where final evaluations will be performed to assess the primary endpoint of EFS.

Participants may be withdrawn from the study early if they experience unacceptable toxicity, withdraw consent, or if the investigator determines it is in their best interest. The trial's design ensures that the investigational product and placebo are indistinguishable to both participants and investigators, maintaining the integrity of the double-blind methodology. The study's rigorous protocol aims to provide robust data on the potential benefits of selpercatinib in this patient population.

The clinical trial involves the administration of **Selpercatinib**, a small molecule kinase inhibitor, as the experimental medication. Selpercatinib is provided in the form of a hard capsule and is administered orally. The specific dosage, frequency, and maximum daily dose are not explicitly defined in the trial data. However, it is noted that the drug substance for clinical trials and commercial use is produced using the same sequence of synthetic steps, ensuring comparable quality and safety. The maximum treatment period for Selpercatinib is specified as one unit of time, though the exact duration is not detailed. Participant compliance with the dosing schedule will be monitored throughout the trial.

The study also includes a **placebo** to match LY3527723, which serves as the comparator treatment. The placebo is designed to mimic the experimental medication in appearance but does not contain any active pharmaceutical ingredients. The pharmaceutical form, route, and frequency of administration for the placebo are not specified in the trial data. The placebo is utilized to maintain the double-blind nature of the study, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thereby reducing bias in the assessment of the trial outcomes.

The efficacy of the investigational product **selpercatinib** will be assessed in a Phase 3 clinical trial involving participants with Stage IB-IIIA RET fusion-positive non-small cell lung cancer (NSCLC). The primary endpoint for evaluating efficacy is the Event-Free Survival (EFS) as determined by investigator assessment in the primary analysis population. This endpoint will be used to compare the efficacy of selpercatinib against a placebo following definitive locoregional treatment. The trial is designed as a placebo-controlled, double-blinded, randomized study to ensure the reliability and validity of the efficacy assessments. The trial will follow a structured schedule for measuring and collecting data on EFS, although specific timepoints for these assessments are not detailed in the provided information. The use of validated scales or specific laboratory tests for efficacy evaluation is not mentioned, and the trial will adhere to standard clinical trial protocols to ensure the accuracy and integrity of the data collected.